ClinicalTrials.gg
Active, not recruitingNCT06101329PURPOSE 3Updated Aug 17, 2026

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

A Phase 2 interventional study of Lenacapavir Tablet and Lenacapavir Injection in Pre-Exposure Prophylaxis of HIV Infection, sponsored by Gilead Sciences. Active, not recruiting at 11 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
253
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 84 studies in HIV Infections by Gilead Sciences — 2 open to participants now, 8 under way, 4 of them phase 3. HIV Infections · Gilead Sciences.

Enrollment
25th of 72
253 · median 131
Started
2023
with 1 other
Phase 2
16 of 84
none open now
Registered
80th of 84
by date

Among the 84 studies in HIV Infections by Gilead Sciences, this one is the 25th largest by enrollment of the 72 interventional ones that give a count, is one of 2 that started in 2023, is one of 16 in phase 2, and was the 80th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

2 of the 84 studies in HIV Infections by Gilead Sciences are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in HIV Infections by Gilead Sciences, or all of them as a file.
02

Study summary

The goal of this clinical study is to look at how lenacapavir (LEN) passes through the body and to assess the safety of LEN and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for prevention of HIV in the cisgender women in the US.

The primary objectives of this study are: 1) to characterize the pharmacokinetics (PK) of LEN in United States (US) cisgender women; 2) to evaluate the safety of LEN and F/TDF for pre-exposure prophylaxis (PrEP) in US cisgender women; and 3) to evaluate the general acceptability of LEN injections and oral F/TDF in US cisgender women.

03

Conditions studied

  • Pre-Exposure Prophylaxis of HIV Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Report at least 1 episode of condomless vaginal or anal sex with a cisgender man in the 12 months before enrollment.
  • virus (HBV) surface antigen (HBsAg) negative.
  • Self-report one or more of the following in the past 12 months (except for incarceration, which could have occurred in the past 5 years):

    1) Noninjection recreational drug use (ecstasy, cocaine, crack cocaine, methamphetamine, ketamine, 3,4-methylenedioxy-methamphetamine, or prescription drugs apart from those prescribed by a licensed provider); 2) Alcohol dependence (defined as Cut Down, Annoyed, Guilty, and Eye Opener score of 2); binge-drinking, defined as 4 or more drinks at a time; 3) History of STIs, such as gonorrhea, chlamydia, or syphilis; 4) Exchange of sex for commodities, such as drugs, money, or shelter; 5) Incarceration (jail or prison > 24 hours within the past 5 years); 6) Two or more sexual partners who were assigned male at birth; 7) Sexual partner assigned male at birth with history of either injection or noninjection recreational drug use, sexually transmitted infections (STIs), (HIV) diagnosis or unknown HIV status, additional sex partners during the course of his sexual relationship with the individual, or incarceration (jail or prison > 24 hours within the past 5 years)

  • Negative local rapid HIV-1/2 antibody (Ab)/antigen (Ag) test, central HIV-1/2 Ab/Ag, and HIV-1 RNA quantitative nucleic acid amplification testing (NAAT).
  • Estimated (GFR) at least 60 mL/min at screening according to the formula for creatinine clearance (CLcr).

Key Exclusion Criteria:

  • Self-reported history of previous positive results on an HIV test.
  • One or more reactive or positive HIV test result at screening or enrollment, even if HIV infection is not confirmed.
  • Past or current participation in HIV vaccine or HIV broadly neutralizing antibody study unless individual provides documentation of receipt of placebo (ie, not active product).
  • Prior use of long-acting systemic pre-exposure prophylaxis (PrEP) (including cabotegravir (CAB) or islatravir studies).
  • Acute viral hepatitis A or acute or chronic hepatitis B or C infection.
  • Severe hepatic impairment or a history of or current clinical decompensated liver cirrhosis (eg, ascites, encephalopathy, variceal bleeding, etc).

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
253 participants (actual)

Study arms

  • Experimental
    Randomized Phase: Lenacapavir (LEN) Group

    Participants will receive subcutaneous (SC) lenacapavir (LEN) 927 mg on Day 1 and Week 26 and oral LEN 600 mg on Days 1 and 2.

    Drug: Lenacapavir Tablet · Drug: Lenacapavir Injection

  • Experimental
    Randomized Phase: Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) Group

    Participants will receive oral F/TDF (200/300 mg) daily for 52 weeks.

    Drug: Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)

  • Experimental
    PK Tail Phase: F/TDF

    After the completion of the Randomized Phase, participants in LEN group will be transitioned to receive F/TDF and participants in F/TDF group will continue to receive F/TDF in the PK Tail Phase. All participants will receive F/TDF, once daily for 78 weeks beginning 26 weeks after the last LEN injection.

    Drug: Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)

Interventions

  • Tablets administered orally without regard of food

    Also known as: GS-6207

  • Injection administered subcutaneously

    Also known as: GS-6207, Yeztugo®

  • DrugEmtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)

    200/300mg fixed dose combination (FDC) tablets administered orally

    Also known as: Truvada®

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) Parameter: Ctrough for Lenacapavir (LEN) at the End of Week 26

    Ctrough is defined as the concentration at the end of the dosing interval.

    Time frame: Week 26

  2. PK Parameter: Ctrough for LEN at the End of Week 52

    Ctrough is defined as the concentration at the end of the dosing interval.

    Time frame: Week 52

  3. Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    Time frame: First dose date up to 30 days post last dose at Week 78

  4. Percentage of Participants Experiencing Treatment-emergent Clinical Laboratory Abnormalities

    Time frame: First dose date up to 30 days post last dose at Week 78

  5. General Acceptability of LEN and F/TDF as PrEP as Assessed by Percentage of Participants with Acceptability Questionnaire Responses

    To assess the acceptability of the study drug, participants will complete the questionnaire including a question on general acceptability of the assigned study drug on an ordinal 5-category scale with a response of: Completely unacceptable, Unacceptable, No opinion, Acceptable, or Completely acceptable.

    Time frame: Up to Week 52

  6. Satisfaction With Use of LEN and F/TDF as PrEP as Assessed by Percentage of Participants with Satisfaction Questionnaire Responses

    To assess the satisfaction with use of the study drug, participants will complete the questionnaire including a question on satisfaction with use of the assigned study drug on an ordinal 5-category scale with a response of: Very satisfied, Satisfied, Neutral, Dissatisfied, or Very dissatisfied.

    Time frame: Up to Week 52

  7. Willingness to Use LEN and F/TDF as PrEP as Assessed by Percentage of Participants with Willingness to Use Questionnaire Responses

    To assess the willingness to use the study drug, participants will complete the questionnaire including a question on willingness to use the assigned study drug on an ordinal 5-category scale with a response of: Definitely Yes, Probably yes, Not sure/undecided, Probably No, or Definitely No.

    Time frame: Up to Week 52

Secondary outcomes

  1. Number of Participants with Adherence to LEN, as Assessed by on-time LEN Injections Received

    Time frame: Up to Week 26

  2. Number of Participants with Adherence to F/TDF, as Assessed by Adherence Levels Based on Tenofovir diphosphate (TFV-DP) Concentrations in Dried Blood Spot (DBS)

    Time frame: Up to Week 78

07

Study locations

11 sites
  • UAB, 1917 Research Clinic
    Birmingham, Alabama 35222, United States
  • UCSD Antiviral Research Center (AVRC)
    San Diego, California 92103, United States
  • George Washington University Medical Faculty Associates
    Washington D.C., District of Columbia 20037, United States
  • Ponce de Leon Center Clinical Research Site
    Atlanta, Georgia 30303, United States
  • Fenway Health
    Boston, Massachusetts 02215, United States
  • Rutgers New Jesey Medical School - Clinical Research Center
    Newark, New Jersey 07103, United States
  • Cornell Clinical Trials Unit, New York Presbyterian Hospital - Weill Cornell Medicine
    New York, New York 10010, United States
  • Harlem Prevention Center CRS
    New York, New York 10027, United States
  • ICAP at Columbia University - Bronx Prevention Center
    The Bronx, New York 10451, United States
  • NC TraCS Institute - CTRC; University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Penn Prevention Research Unit
    Philadelphia, Pennsylvania 19104, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jul 2026, 32 months.

Of 34 industry-sponsored phase 2 interventional studies under HIV Infections, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 32 months is above that.

Counting every sponsor, half of 98 studies reached it within 31 months; a quarter within 17 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2023
First posted
Oct 26, 2023
StartActual
Nov 17, 2023
Primary completionActual
Jul 22, 2026
CompletionEst.
Jan 2028
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06101329
Lead sponsor
Gilead Sciences
Collaborators
HIV Prevention Trials Network
Responsible party
Sponsor
First posted
Oct 26, 2023
Start date
Nov 17, 2023
Primary completion
Jul 22, 2026
Completion
Jan 2028 (estimated)
Last update
Aug 17, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenacapavir

Start the discussion